Endorse the #Wins4TBVax
Endorse the #Wins4TBVax
The Working Group on New TB Vaccines
New vaccines are essential to ending the tuberculosis (TB) pandemic. The Stop TB Partnership Working Group on New TB Vaccines (WGNV) helps to facilitate the development of new, more effective TB vaccines by promoting consensus, scientific exchange, and advocacy in support of TB research and development (R&D).
The Working Group
on New TB Vaccines
New vaccines are essential to ending the global tuberculosis (TB) epidemic. The Stop TB Partnership Working Group on New TB Vaccines (WGNV) helps to facilitate the development of new, more effective TB vaccines by promoting consensus, scientific exchange, and advocacy in support of TB research and development (R&D).
The World URGENTLY Needs New TB VaccineS
TB remains a major global health threat. In 2022, an estimated 10.6 million people became sick with TB and 1.3 million people died from TB.
The only licensed vaccine to prevent TB – the 100-year old BCG vaccine – provides moderate, although important, protection against severe TB in infants and young children, but it does not adequately protect adolescents and adults, who are most at risk for developing and spreading TB.
Multiple new TB vaccines that work across all populations and age groups, particularly among adults and adolescents, will be critical to eliminate TB by 2030 and meet the WHO End TB targets.
Our Mission
The mission of the WGNV is to facilitate research and development of new TB vaccines by providing an inclusive forum for stakeholders to engage in scientific exchange, build consensus on key issues, and advocate for greater support and investment in TB vaccine R&D.
The WGNV facilitates the development of new, more effective TB vaccines by:
Promoting collaboration and cooperation among multiple stakeholders
Providing a forum to discuss challenges to TB vaccine R&D and identify solutions
Helping to build consensus on key issues and questions related to TB vaccine R&D
Advocating for increased support and investment in TB vaccine R&D
The WGNV also serves as the mechanism of exchange and dialogue between the Stop TB Partnership and the TB implementation, care, advocacy, and TB vaccine research communities.
The WGNV facilitates the development of new, more effective TB vaccines by:
Promoting collaboration and cooperation among multiple stakeholders
Providing a forum to discuss challenges to TB vaccine R&D and identify solutions
Helping to build consensus on key issues and questions related to TB vaccine R&D
Advocating for increased support and investment in TB vaccine R&D
The WGNV also serves as the mechanism of exchange and dialogue between the Stop TB Partnership and the TB implementation, care, advocacy, and TB vaccine research communities.
TB Vaccine Pipeline
The TB Vaccine Pipeline tracks the research and development of TB vaccine candidates through different phases of development, from pre-clinical to late-stage testing.
